AbbVie and FutureGen Biopharmaceutical Co., Ltd. have entered into a license agreement to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD. FG-M701 is a fully human monoclonal antibody targeting TL1A, a target in IBD. The antibody is engineered
Minaris Regenerative Medicine GmbH, a contract development and manufacturing organization (CDMO) for cell and gene therapies, has taken a significant step towards digital transformation. The company has implemented the newest version of Werum PAS-X MES by Körber, a digital Manufacturing
Asahi Kasei has launched a new membrane system designed to produce Water for Injection (WFI), a type of sterile water used in the preparation of injections. This innovative system was developed as an alternative to conventional distillation processes, leveraging the design
BioCina Pty Ltd. has announced an exclusive agreement to utilise CelluTx’s recombination-based plasmid system (RBPS) technology with its CDMO clients. The RBPS technology is a novel method for minicircle DNA (mcDNA) production, which involves site-specific recombination within a bacterial host. This
Merck, a global player in the life science sector, has announced the opening of its expanded distribution center in Schnelldorf, Germany. The expansion, which cost €180 million, added 25,000 square meters to the site, almost doubling its size. The site
Siegfried has announced the acquisition of a new site that specialises in early-phase development and manufacturing services. The site, staffed by an experienced team of over 80 employees, is expected to enhance Siegfried’s customer offering for Drug Substances in terms of
Essential Pharma has entered into a strategic agreement with AGC Biologics for the production of Hu14.18, a humanized monoclonal antibody. This antibody is currently under development for the treatment of high-risk neuroblastoma (HRNB), a rare and aggressive form of cancer that
Freudenberg Medical, a global contract design and manufacturing (CDMO) partner to the medical device and biopharma industry, is making a substantial investment in its drug device combination products business. The company is investing more than $50 million in a new
Charles River Laboratories, a global provider of products and services to accelerate the research, drug discovery, and drug development process, has announced a new program to develop an inhalation toxicology test. This initiative aims to reduce the reliance on traditional
Asgard Therapeutics, a biotech company specialising in in vivo direct cell reprogramming for cancer immunotherapy, has announced its selection of Exothera S.A. for the process development and clinical Phases I/II manufacturing of its candidate AT-108. The candidate is based on
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
